Wet Age-related Macular Degeneration Treatment Perspectives – New Promising Drugs in Development
str. 11 – 14
Autorzy: Ewelina Lachowicz, Wojciech Lubiński
II Katedra i Klinika Okulistyki Pomorskiego Uniwersytetu Medycznego w Szczecinie
Samodzielny Publiczny Szpital Kliniczny nr 2 w Szczecinie
Kierownik: prof. dr hab. n. med., FEBO Wojciech Lubiński
Summary: The wet age-related macular degeneration is a complex disease with angiogenic and inflammatory components. The new pharmacological factors directing multiple targets in its pathophysiology are under evaluation. While some products are already available in human clinical trials or even the United States Food and Drug Administration and the European Medicines Agency – approved, most are still under experimental investigation and little is known about them. In this review, we will discuss promising new therapies for wet age-related macular degeneration that aim to improve outcomes, safety and treatment inconvenience through novel mechanisms of action. Due to its historical significance, we also described the most important drugs that did not achieve the desired clinical effects and never left the phase of clinical trials.
Słowa kluczowe: zwyrodnienie plamki związane z wiekiem (AMD), wysiękowa postać zwyrodnienia plamki związanego z wiekiem (wAMD), terapia, nowe leki.
Keywords: age-related macular degeneration (AMD), wet age-related macular degeneration (wAMD), treatment, new drugs.